Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients
- 23 October 2025
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1007, 178290
Abstract
No abstract availableKeywords
Funding Information
- Uniwersytet Medyczny w Białymstoku
- Uniwersytet Medyczny w Bialymstoku (B.SUB.25.103)
This publication has 105 references indexed in Scilit:
- Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor typesGeroScience, 2025
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesJAMA Network Open, 2024
- Obesity enhances the response to neoadjuvant anti‐ PD1 therapy in oral tongue squamous cell carcinomaCancer Medicine, 2024
- Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 DiabetesJAMA Network Open, 2024
- Glucagon‐like peptide‐1 therapy in people with obesity restores natural killer cell metabolism and effector functionObesity, 2023
- A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretionJournal of Molecular Medicine, 2017
- Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophagesBasic Research in Cardiology, 2015
- β-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in miceDiabetologia, 2013
- The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cellsBreast Cancer Research and Treatment, 2011
- Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?Diabetologia, 2009